- Home
- BTAI vs KOSS Comparison
BTAI vs KOSS Comparison
Compare BTAI & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- KOSS
- Stock Information
- Founded
- BTAI 2017
- KOSS 1953
- Country
- BTAI United States
- KOSS United States
- Employees
- BTAI N/A
- KOSS N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- KOSS Consumer Electronics/Appliances
- Sector
- BTAI Health Care
- KOSS Consumer Staples
- Exchange
- BTAI Nasdaq
- KOSS Nasdaq
- Market Cap
- BTAI 52.7M
- KOSS 57.5M
- IPO Year
- BTAI 2018
- KOSS N/A
- Fundamental
- Price
- BTAI $3.79
- KOSS $6.15
- Analyst Decision
- BTAI Strong Buy
- KOSS
- Analyst Count
- BTAI 4
- KOSS 0
- Target Price
- BTAI $40.00
- KOSS N/A
- AVG Volume (30 Days)
- BTAI 14.1M
- KOSS 72.6K
- Earning Date
- BTAI 08-12-2025
- KOSS 10-30-2025
- Dividend Yield
- BTAI N/A
- KOSS N/A
- EPS Growth
- BTAI N/A
- KOSS N/A
- EPS
- BTAI N/A
- KOSS N/A
- Revenue
- BTAI $868,000.00
- KOSS $12,624,170.00
- Revenue This Year
- BTAI N/A
- KOSS N/A
- Revenue Next Year
- BTAI $597.46
- KOSS N/A
- P/E Ratio
- BTAI N/A
- KOSS N/A
- Revenue Growth
- BTAI N/A
- KOSS 2.93
- 52 Week Low
- BTAI $1.17
- KOSS $4.00
- 52 Week High
- BTAI $13.36
- KOSS $8.59
- Technical
- Relative Strength Index (RSI)
- BTAI 48.02
- KOSS 54.94
- Support Level
- BTAI $3.41
- KOSS $6.03
- Resistance Level
- BTAI $4.20
- KOSS $6.33
- Average True Range (ATR)
- BTAI 0.62
- KOSS 0.38
- MACD
- BTAI -0.27
- KOSS -0.03
- Stochastic Oscillator
- BTAI 11.05
- KOSS 36.59
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.